Taken together, in BCR-ABL-positive cells, STAT2 was found to be a survival factor but not an IFNa-sensitizing factor, indicating an important role of STAT2 protein in the prediction of responsiveness of CML patients to IFNa therapy. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.